Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 1Agammaglobulinemia 1

Interventions

venetoclax 72Specimen Handling 67Cyclophosphamide 57Cytarabine 51Biopsy 49fludarabine 42Azacitidine 37Rituximab 27fludarabine phosphate 21Magnetic Resonance Spectroscopy 21Vincristine 20Methotrexate 20blinatumomab 19Daunorubicin 19Prednisone 17ibrutinib 16Whole-Body Irradiation 16Injections 16Dexamethasone 16decitabine and cedazuridine drug combination 15Tacrolimus 14Mycophenolic Acid 14obinutuzumab 13Melphalan 13Granulocyte Colony-Stimulating Factor 13Doxorubicin 13Busulfan 13merphos 12acalabrutinib 12Stem Cell Transplantation 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Panzyga × Other hematologic neoplasm × 30 days × Clear all
NCT04502030 2026-06-04

Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)

Octapharma

Phase 3 Completed
247 enrolled
LymphoidOther hematologic neoplasm

Agammaglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡